SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 28th, 2024 • Xilio Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 28th, 2024 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of March 28, 2024 (the “Execution Date”) by and among Xilio Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 12th, 2022 • SAB Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledDecember 12th, 2022 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 6, 2022 (the “Effective Date”) by and among SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 11th, 2022 • Immunic, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 11th, 2022 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of October 10, 2022 by and among Immunic, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 2nd, 2016 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 2nd, 2016 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 27, 2016 by and among Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).